Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12607832 | 0.96 | PARP1 (0.39) | PARP1PARP2MAP4K1USP30HRH3 | |
| Trifluoroacetic Acid SCHEMBL3339970 | 0.92 | PARP1 (0.36) | PARP1PARP2MAP4K1BDKRB1 | |
| SCHEMBL12607827 | 0.86 | MAP4K1 (0.39) | PARP1PARP2MAP4K1 | |
| SCHEMBL3342713 | 0.82 | MAP4K1 (0.38) | MAP4K1USP30BDKRB1 | |
| Trifluoroacetic Acid SCHEMBL3343257 | 0.80 | MAP4K1 (0.46) | MAP4K1HRH3 | |
| SCHEMBL1786382 | 0.78 | MAP4K1 (0.44) | MAP4K1HRH3 | |
| SCHEMBL16194801 | 0.78 | MAP4K1 (0.38) | MAP4K1BDKRB1 | |
| Hydrochloric Acid SCHEMBL3340501 | 0.77 | MAP4K1 (0.44) | MAP4K1HRH3 | |
| Trifluoroacetic Acid SCHEMBL3339828 | 0.76 | MCHR1 (0.44) | MAP4K1USP30HRH3 | |
| Trifluoroacetic Acid SCHEMBL3339550 | 0.75 | DPP4 (0.42) | MAP4K1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | PARP1 4636/4885PARP2 4265/4885MAP4K1 2850/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | PARP1 4618/4885PARP2 4515/4885MAP4K1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.